FDA’s new expert panels are rife with financial conflicts and fringe views—
A series of panels convened by the Food and Drug Administration is raising concerns that the agency is skirting federal rules and promoting fringe views about antidepressants and other products
FDA’s new expert panels are rife with financial conflicts and fringe viewsBy MATTHEW PERRONEAP Health WriterThe Associated PressWASHINGTON
WASHINGTON (AP) — When the Food and Drug Administration needs outside guidance, it normally turns to a trusted source: a large roster of expert advisers who are carefully vetted for their independence, credentials and judgment.
